Repligen (RGEN) Fundamentals 2026 — P/E 155.0x, Revenue Analysis | SniperIQ

41.05 on the NASDAQ. This SniperIQ fundamentals page covers Repligen's valuation (P/E 155.0x, P/B 3.8x), profitability (net margin 6.7%), revenue ($738M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Repligen's market cap?

Repligen (RGEN) has a market capitalization of approximately $8.0B, trading at

41.05 on the NASDAQ. Market cap moves with the live share price.

What is Repligen's P/E ratio?

Repligen's trailing twelve-month P/E ratio is 155.0x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Repligen?

Repligen runs a net profit margin of 6.7%, a gross margin of 50.3%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Repligen generate?

Repligen reported revenue of $738M for fiscal year 2025, with net income of $49M and earnings per share (EPS) of 0.87. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Repligen pay a dividend?

Repligen does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Repligen financially healthy?

Repligen carries a debt-to-equity ratio of 0.33x and a current ratio of 9.20x, with a market beta of 1.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Repligen a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Repligen (RGEN) the key facts are: market cap $8.0B, P/E 155.0x, revenue $738M, 52-week range 100.99-175.77. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.